

Laura Romero-PÃ©rez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8711019/publications.pdf>

Version: 2024-02-01

28
papers

1,610
citations

361413

20
h-index

501196

28
g-index

38
all docs

38
docs citations

38
times ranked

3384
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. <i>Molecular Cancer</i> , 2022, 21, 1.	19.2	25
2	Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. <i>Molecular Cancer</i> , 2021, 20, 97.	19.2	24
3	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. <i>Nature Communications</i> , 2021, 12, 5356.	12.8	11
4	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
5	Integrative clinical transcriptome analysis reveals <i>TMPRSS2</i> dependency of prognostic biomarkers in prostate adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2036-2046.	5.1	13
6	Hippo pathway effectors YAP1/TAZ induce an <i>EWS</i> opposing gene signature and associate with disease progression in Ewing sarcoma. <i>Journal of Pathology</i> , 2020, 250, 374-386.	4.5	19
7	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	2.5	29
8	Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. <i>Nature Communications</i> , 2020, 11, 2423.	12.8	35
9	High Specificity of <i>BCL11B</i> and <i>GLG1</i> for <i>EWSR1-FLI1</i> and <i>EWSR1-ERG</i> Positive Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 644.	3.7	16
10	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1353-1362.	4.2	34
11	STAG Mutations in Cancer. <i>Trends in Cancer</i> , 2019, 5, 506-520.	7.4	38
12	Gene expression and immunohistochemical analyses identify <i>SOX2</i> as major risk factor for overall survival and relapse in Ewing sarcoma patients. <i>EBioMedicine</i> , 2019, 47, 156-162.	6.1	23
13	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. <i>Nature Communications</i> , 2019, 10, 4128.	12.8	51
14	DNA methylation profiling distinguishes Ewing-like sarcoma with <i>EWSR1-NFATc2</i> fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281.	2.5	50
15	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. <i>Nature</i> , 2019, 566, 403-406.	27.8	326
16	Targeting the <i>CALCB/RAMP1</i> axis inhibits growth of Ewing sarcoma. <i>Cell Death and Disease</i> , 2019, 10, 116.	6.3	23
17	Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 2228-2240.	7.0	44
18	Functional genomics identifies <i>AMPD2</i> as a new prognostic marker for undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2019, 144, 859-867.	5.1	10

#	ARTICLE	IF	CITATIONS
19	Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel. <i>Scientific Reports</i> , 2016, 6, 23910.	3.3	51
20	Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 443-454.	3.1	66
21	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , 2015, 28, 1492-1503.	5.5	23
22	VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 587-599.	3.1	53
23	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. <i>Human Pathology</i> , 2013, 44, 244-254.	2.0	30
24	Oncogene alterations in endometrial carcinosarcomas. <i>Human Pathology</i> , 2013, 44, 852-859.	2.0	27
25	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. <i>Modern Pathology</i> , 2013, 26, 1514-1524.	5.5	68
26	Genetics of Endometrial Carcinoma. , 2013, , 349-390.		1
27	MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes. <i>PLoS ONE</i> , 2012, 7, e47709.	2.5	85
28	MicroRNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , 2011, 223, 72-80.	4.5	194